UPDATE: Jefferies Reiterates Buy Rating, Raises PT on Mednax Following Recent Plateauing

In a report published Tuesday, Jefferies analyst Brian Tanquilut reiterated a Buy rating on Mednax MD, and raised the price target from $95.00 to $108.00. In the report, Jefferies noted, “We continue to have a very positive bias on MD and view the stock's recent plateauing as a compelling opportunity to build positions in a growthy name that has a number of upside-driving positive catalysts on the horizon (bump in Medicaid rates likely by Q3 and plans for numerous accretive acquisitions between now and year-end). Raising PT to $108.” Mednax closed on Friday at $91.95.
Market News and Data brought to you by Benzinga APIs
Comments
Loading...
date
ticker
name
Price Target
Upside/Downside
Recommendation
Firm
Posted In: Analyst ColorPrice TargetAnalyst RatingsBrian TanquilutJefferies
Benzinga simplifies the market for smarter investing

Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.

Join Now: Free!